Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCT-402 in relapsed/refractory B-ALL
NCT02669264Phase 1Terminated
- Sponsor
- ADC Therapeutics
- Start
- Mar 2016
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of loncastuximab tesirine in B cell acute lymphoblastic leukemia (B-ALL) (2 arms), sponsored by ADC Therapeutics. Primary endpoints: Number of Participants Who Experienced Dose-Limiting Toxicities, Recommended Dose of ADCT-402 for Part 2 and 2 more. Started Mar 2016; status: terminated.
02
Drugs
loncastuximab tesirine
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02669264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669264.